New insider activity at Exelixis ( (EXEL) ) has taken place on November 26, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director David Edward Johnson has made a significant investment in Exelixis by purchasing 27,532 shares of the company’s stock, valued at $1,187,179.
Recent Updates on EXEL stock
In the last 24 hours, Exelixis has seen significant developments following its Q3 earnings call, which highlighted strong financial performance and strategic advancements in the oncology sector. The company reported total revenues of approximately $598 million, with the cabozantinib franchise contributing significantly to this growth. Analysts have adjusted their price targets for Exelixis, citing the company’s robust revenue growth, successful market penetration of CABOMETYX in neuroendocrine tumors, and promising clinical trial results for zanzalintinib, particularly in colorectal cancer. However, concerns remain about potential regulatory delays and restructuring charges. Despite these challenges, Exelixis’s strategic positioning and market prospects have led to positive outlooks from analysts. The company’s commitment to innovation and shareholder value, as demonstrated by its substantial share repurchase program, further supports this optimism.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
Exelixis’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust revenue growth, efficient cost management, and strategic advancements in its R&D pipeline contribute to a favorable outlook. However, technical indicators suggest a bearish trend, and valuation metrics indicate fair pricing, which slightly tempers the overall score.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
YTD Price Performance: 27.08%
Average Trading Volume: 2,762,178
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.56B